A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1148 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Advate | N.A. | Powder form | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1149 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Alphanate | N.A. | Lyophilized powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1150 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Bioclate | Baxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Sterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Intravenous infusion | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1151 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Helixate FS | N.A. | Sterile, stable, purified, nonpyrogenic, dried concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1152 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hemofil M | N.A. | Dry concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1153 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hyate:C | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1154 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Koate-HP | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1155 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Kogenate FS | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1156 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Monarc-M | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1157 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Monoclate-P | N.A. | Lyophilized powder for solution | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1158 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | ReFacto | N.A. | Lyophilized powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1159 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Xyntha | N.A. | Sterile, nonpyrogenic, preservative-free, freeze-dried powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1205 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Humulin R | Eli Lilly and Company | Sterile, clear, aqueous, and colorless solution | Subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
| 1206 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Novolin R | Novo Nordisk | Sterile, clear, aqueous, and colorless solution | Subcutaneous and Intravenous infusion | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
| 1210 | Th1028 | Tenecteplase | SYQVICRDEKTQMIYQQHQS Full view | 255 | Ib | Hematological,Metabolic | TNKase | Genentech Inc | Sterile, white to off-white, lyophilized powder | Intravenous Injection | Thrombolytic Agents, Fibrinolytic agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1,Plasminogen activator inhibitor 2,Tetranectin,Keratin, type II cytoskeletal 8,Annexin A2,Calreticulin,Calnexin,Prolow-density lipoprotein |
| 1246 | Th1034 | Palifermin | SYDYMEGGDIRVRRLFCRTQ Full view | 140 | Ib | Cancer | Kepivance | Amgen Inc | Sterile, lyophilized powder | Intravenous infusion | Anti-Mucositis Agents | Fibroblast growth factor receptor 2,Neuropilin-1,Fibroblast growth factor receptor 1,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 3,Basement membrane-specific heparan sulfate proteoglycan core protein |
| 1260 | Th1037 | Botulinum Toxin Type B | MPVTINNFNYNDPIDNNNII Full view | 255 | Ic | Neurological Disorder | Myobloc | Solstice Neurosciences | Clear and colorless to light-yellow sterile injectable solution | Injection | Antidystonic Agents | Vesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
| 1261 | Th1037 | Botulinum Toxin Type B | MPVTINNFNYNDPIDNNNII Full view | 255 | Ic | Neurological Disorder | Neurobloc | Solstice Neurosciences | Clear and colourless to light yellow solution | Intramuscular Injection | Antidystonic Agents | Vesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
| 1358 | Th1050 | Pegademase bovine | MAQTPAFNKPKVELHVHLDG Full view | 255 | Ia | Metabolic | Adagen | Enzon Inc. | Isotonic, pyrogen free, sterile solution, pH 7.2-7.4 | Intramusular Injection | Enzyme Replacement Agents | Adenosine,Growth factor receptor-bound protein 2 |
| 1365 | Th1053 | Serum albumin iodonated | MKWVTFISLLFLFSSAYSRG Full view | 600 | IV | Hematological Disorders | Megatope | IsoTex Diagnostics | Colorless to very pale yellow solutions | Injection for Intravenous administration | Diagnostic Agents | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
| 1366 | Th1053 | Serum albumin iodonated | MKWVTFISLLFLFSSAYSRG Full view | 600 | IV | Hematological Disorders | Jeanotope | IsoTex Diagnostics | Sterile, nonpyrogenic, aqueos solution | Intravenous infusion | Diagnostic Agents | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
| 1367 | Th1053 | Serum albumin iodonated | MKWVTFISLLFLFSSAYSRG Full view | 600 | IV | Hematological Disorders | Volumex | IsoTex Diagnostics | Colorless to very pale yellow. | Intravenous infusion | Diagnostic Agents | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
| 1385 | Th1061 | Trastuzumab | Light chain 1: DIQMT Full view | 1364 | IIa | Cancer | Herceptin | Genentech | Sterile, white to pale yellow, preservative-free lyophilized powder |  Intravenous administration | Antineoplastic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
| 1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
| 1403 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DIGIBIND | Galaxo Smith Kline | Sterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep. | Intravenous infusion after reconstitution with Sterile Water for Injection | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1404 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DigiFab |  Protherics Inc | Sterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. | Intravenous administration | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1422 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Pancrecarb | Digestive care US, Inc. | Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres. | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1423 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Viokace | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet form | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1424 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRESA | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1425 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | PERTZYE | Digestive care US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether PERTZYE delayed-release capsule | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1426 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRASE | Axcan Pharma | Capsules Enteric-Coated Microspheres | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1427 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ZENPEP | Aptalis Pharma US, Inc. | Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1434 | Th1074 | Alglucerase | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Metabolic | Ceredase | Genzyme Corporation | Clear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Intravenous injection | Enzyme Replacement Agents | Plasminogen,Proteinase-activated receptor 1 |
| 1454 | Th1084 | Becaplermin | SLGSLTIAEPAMIAECKTRT Full view | 109 | Ib | Cardiac | REGRANEX | OMJ Pharmaceuticals, Inc. San German, Puerto Rico | Gel: 0.01 %; clear, colorless to straw-colored gel | External use only | Angiogenesis Inducing Agents | T-cell surface glycoprotein CD1a,Major histocompatibility complex class I-related gene protein,Integrin alpha-L,T-lymphocyte activation antigen CD86,Low affinity immunoglobulin gamma Fc region receptor II-b,T-cell surface glycoprotein CD4,Integrin beta-1,Integrin alpha-V,Integrin beta-3 |
| 1456 | Th1086 | Interferon Alfa-2B, Recombinant | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | INTRON® A | Merck | Powder or solution | Intramuscular, Subcutaneous, Intralesional, or Intravenous injection | Immunosuppressive Agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
| 1462 | Th1088 | Enfuvirtide | YTSLIHSLIEESQNQQEKNE Full view | 36 | IIa | Infectious | `FUZEON | Trimeris, Roche | White to off-white, sterile, lyophilized powder. | Subcutaneous injection | HIV Fusion Inhibitors | Oxytocin receptor,Oxytocin-neurophysin 1, Envelope glycoprotein |
| 1466 | Th1090 | Daclizumab | QVQLVQSGAEVKKPGSSVKV Full view | 674 | IIa | Immunologicals | Zenapax | Roche | Clear, sterile, colorless concentrate for further dilution and intravenous administration | Intravenous injection | Immunosuppressive Agents | Fusion glycoprotein F0,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1480 | Th1099 | Mecasermin | GPETLCGAELVDALQFVCGD Full view | 70 | Ib | Hormonal | N.A. | N.A. | N.A. | N.A. | N.A. | Insulin-like growth factor 1 receptor,Insulin-like growth factor-binding protein 3,Insulin receptor,Cation-independent mannose-6-phosphate receptor |
| 1482 | Th1100 | Pramlintide | KCNTATCATQRLANFLVHSS Full view | 37 | Ia | Hormonal/Metabolic | Symlin | Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca) | Clear, isotonic, sterile solution | Subcutaneous injection | N.A. | Calcitonin receptor,Receptor activity-modifying protein 1,Receptor activity-modifying protein 2,Receptor activity-modifying protein 3 |
| 1548 | Th1117 | Ipilimumab | Heavy chain: QVQLVES Full view | 663 | IIIc | Cancer | YERVOY | Bristol-Myers Squibb | Sterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution | N.A. | Antineoplastic Agents and Monoclonal antibodies | Cytotoxic T-lymphocyte protein 4 |
| 1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
| 1562 | Th1122 | Rilonacept | rilonacept|Homo sapi Full view | 880 | IIa | Immunological | Arcalyst | Regeneron Pharmaceuticals | Sterile, white to off-white, lyophilized powder | Subcutaneous injection | Immunosuppressive Agents | Interleukin-1 beta,Interleukin-1 alpha,Interleukin-1 receptor antagonist protein |
| 1659 | Th1152 | Drotrecogin alfa | Heavy Chain: LIDGKMT Full view | 402 | Ib | Infectious | Xigris | Eli Lilly and Company | Sterile, lyophilized, white to off-white powder | Intravenous Infusion | Antisepsis | Coagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
| 1663 | Th1155 | Urokinase | KPSSPPEELKFQCGQKTLRP Full view | 276 | Ib | Haemetological | Kinlytic | N.A. | Sterile lyophilized white powder | Intravenous infusion | N.A. | Plasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
| 1673 | Th1160 | Satumomab Pendetide | Heavy Chain 1: QVQLQ Full view | 1299 | IV | Diagnostic Agents | OncoScint | Cytogen Corp, Lonza Biologics | N.A. | Intravenous Injection | Diagnostic Agents | Tumor-associated glycoprotein 72 (TAG-72) |
| 1678 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 9 |
| 1679 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 10 |
| 1680 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 11 |
| 1681 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 14 |
| 1708 | Th1170 | Blinatumomab | DIQLTQSPASLAVSLGQRAT Full view | 504 | IIIc | Cancer/Genetic | Blincyto | AMGEN | Lyophilized Powder for intravenous administration | Intravenous | Antineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents | B-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain |